GHRP-6 vs Ipamorelin: Side Effect Profiles
Comparative analysis of GHRP-6 and ipamorelin side effect profiles, covering growth hormone secretagogue adverse events, corticotropin effects, appetite stimulation, and tolerability.
GHRP-6 vs Ipamorelin: Side Effect Profiles
Introduction
GHRP-6 (Growth Hormone Releasing Peptide-6) and ipamorelin are growth hormone secretagogues (GHS) that stimulate GH release through the ghrelin receptor (GHSR-1a). Despite sharing the same primary receptor, they exhibit substantially different side effect profiles due to differences in receptor selectivity, signaling bias, and off-target activity.
Agent Characteristics
| Parameter | GHRP-6 | Ipamorelin |
|---|---|---|
| Amino acid count | 6 | 5 |
| Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ | Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
| Molecular weight | ~873 Da | ~712 Da |
| Selectivity | Non-selective GHSR/CD36 | Selective GHSR-1a |
| Half-life | ~20 minutes | ~2 hours |
| Route | SC/IV/IN | SC/IV |
Mechanism of Action
GHRP-6
GHRP-6 activates multiple pathways:
Primary: GHSR-1a Agonism
- Stimulates GH release from somatotrophs
- Activates hypothalamic GH release hormone (GHRH) neurons
- Synergizes with endogenous GHRH
Off-Target: CD36 Activation
- Binds CD36 (fatty acid translocase) on macrophages
- Promotes inflammatory cytokine release
- Activates NF-κB pathway
- Contributes to cortisol elevation
Other Off-Target Effects
- ACTH co-secretion (via CRH stimulation)
- Prolactin elevation
- Aldosterone stimulation
- Cortisol elevation (more pronounced than ipamorelin)
Ipamorelin
Ipamorelin exhibits cleaner receptor selectivity:
Primary: GHSR-1a Agonism
- Stimulates GH release from somatotrophs
- Minimal off-target receptor activity
- Selective signaling (Gq/11 pathway)
Minimal Off-Target Effects
- Weak CD36 binding (negligible)
- Minimal ACTH co-secretion
- Minimal cortisol elevation
- No significant prolactin effect
Side Effect Comparison
Endocrine Effects
| Side Effect | GHRP-6 | Ipamorelin | Mechanism |
|---|---|---|---|
| Cortisol elevation | Significant (20–50%) | Minimal (<10%) | ACTH co-secretion |
| ACTH elevation | Moderate-Severe | Minimal | Direct CRH stimulation |
| Prolactin elevation | Moderate | Minimal | Direct lactotroph effect |
| Aldosterone elevation | Moderate | Minimal | Direct adrenal effect |
| TSH suppression | Possible | Minimal | Somatostatin interaction |
| IGF-1 elevation | Strong | Moderate-Strong | GH-dependent |
| GH pulse amplitude | Large | Moderate | Receptor signaling |
Metabolic Effects
| Side Effect | GHRP-6 | Ipamorelin | Mechanism |
|---|---|---|---|
| Appetite stimulation | Very strong | Mild-Moderate | Hypothalamic NPY activation |
| Glucose elevation | Moderate | Mild | GH-mediated insulin resistance |
| Insulin resistance | Moderate-Severe | Mild | GH counter-regulatory effects |
| Lipid changes | Moderate | Minimal | GH-mediated lipolysis |
| Water retention | Moderate | Mild | GH/IGF-1 effects |
Gastrointestinal
| Side Effect | GHRP-6 | Ipamorelin | Mechanism |
|---|---|---|---|
| Nausea | 20–40% | 5–15% | Central (area postrema) |
| Vomiting | 10–20% | 2–5% | Central emetic |
| Hunger sensation | Very common | Moderate | NPY/AgRP activation |
| Gastric motility changes | Moderate | Minimal | Direct GI effects |
| Bloating | 10–20% | 5–10% | GI motility |
Cardiovascular
| Side Effect | GHRP-6 | Ipamorelin | Mechanism |
|---|---|---|---|
| Blood pressure increase | Moderate | Minimal | Aldosterone/AVP |
| Heart rate increase | Mild | Minimal | Direct chronotropic |
| Cardiac output increase | Moderate | Mild | GH-mediated |
| QTc prolongation | Possible | Rare | Unknown |
Musculoskeletal
| Side Effect | GHRP-6 | Ipamorelin | Mechanism |
|---|---|---|---|
| Joint pain | 5–10% | 2–5% | GH-mediated |
| Muscle soreness | 5–10% | 2–5% | GH-mediated |
| Carpal tunnel | Rare | Rare | Fluid retention |
| Arthralgia | 5–10% | 2–5% | GH-mediated |
Neurological
| Side Effect | GHRP-6 | Ipamorelin | Mechanism |
|---|---|---|---|
| Dizziness | 10–20% | 3–5% | Hypotension/central |
| Headache | 10–15% | 5–10% | Vasodilation |
| Fatigue | 10–15% | 5–10% | Central |
| Flushing | 10–20% | 5–10% | Vasodilation |
| Tingling/paresthesia | 5–10% | 2–5% | Peripheral nerve |
Tolerability Assessment
Overall Tolerability Ranking
| Parameter | GHRP-6 | Ipamorelin |
|---|---|---|
| Overall tolerability | Moderate | Good |
| Dose-limiting side effects | Appetite, cortisol | Minimal |
| Treatment discontinuation rate | 15–25% | 5–10% |
| Side effect severity | Moderate-Severe | Mild-Moderate |
| Long-term tolerability | Concerns | Favorable |
Side Effect Incidence Summary
| Side Effect Category | GHRP-6 | Ipamorelin |
|---|---|---|
| Endocrine (cortisol, ACTH) | High | Low |
| GI (nausea, hunger) | Very High | Moderate |
| Cardiovascular | Moderate | Low |
| Neurological | Moderate | Low |
| Musculoskeletal | Low-Moderate | Low |
| Metabolic (glucose) | Moderate | Low |
Dosing Considerations
GHRP-6
| Dose | Side Effect Profile |
|---|---|
| 50–100 mcg | Mild side effects, moderate hunger |
| 100–200 mcg | Moderate side effects, significant hunger |
| 200–300 mcg | More pronounced cortisol, strong hunger |
| 300–500 mcg | High cortisol, severe hunger, nausea |
Ipamorelin
| Dose | Side Effect Profile |
|---|---|
| 50–100 mcg | Minimal side effects |
| 100–200 mcg | Mild side effects |
| 200–300 mcg | Moderate side effects |
| 300–500 mcg | Slightly more pronounced (still well-tolerated) |
Safety Monitoring
Recommended Monitoring
| Test | GHRP-6 Frequency | Ipamorelin Frequency |
|---|---|---|
| IGF-1 | Every 4 weeks | Every 8 weeks |
| Fasting glucose | Every 4 weeks | Every 8 weeks |
| Cortisol (AM) | Every 4 weeks | Every 8–12 weeks |
| ACTH | Every 4–8 weeks | Baseline + as needed |
| Prolactin | Baseline + as needed | Baseline only |
| Liver function | Baseline + as needed | Baseline only |
| Lipid profile | Baseline + every 12 weeks | Baseline + every 12 weeks |
Dose Adjustment Triggers
| Parameter | GHRP-6 | Ipamorelin |
|---|---|---|
| Cortisol >2× upper normal | Reduce dose 25–50% | Rare (monitor) |
| Glucose >140 mg/dL fasting | Reduce dose, dietary modification | Adjust if needed |
| Severe nausea | Reduce dose, split dosing | Reduce dose |
| Prolactin >2× upper normal | Reduce dose or switch | Rare |
Mitigation Strategies
For GHRP-6 Side Effects
Appetite Management
- Split dosing (2–3× daily instead of bolus)
- High-protein, high-fiber diet
- Timed meals around dosing
- Gradual dose titration
Cortisol Elevation
- Monitor AM cortisol levels
- Consider cortisol-lowering agents (if clinically significant)
- Reduce dose if cortisol persistently elevated
- Consider switching to ipamorelin
Nausea
- Take with small meal
- Anti-emetic pre-medication (ondansetron)
- Subcutaneous route (less nausea than IV)
- Lower dose, increase frequency
For Ipamorelin Side Effects
Mild Nausea
- Take with food
- Subcutaneous route
- Lower initial dose, titrate up
Injection Site Reactions
- Rotate injection sites
- Use proper technique
- Ensure reconstituted solution is room temperature
Conclusion
Ipamorelin demonstrates a substantially cleaner side effect profile than GHRP-6, primarily due to its selective GHSR-1a agonism without significant off-target activity. GHRP-6’s non-selective receptor profile produces more pronounced cortisol elevation, appetite stimulation, and GI side effects. For patients requiring growth hormone secretagogue therapy, ipamorelin is generally preferred for its superior tolerability, lower endocrine disruption, and more favorable long-term safety profile. GHRP-6 may be considered in specific clinical contexts where its more potent GH stimulation is required, but with closer monitoring of cortisol, glucose, and appetite effects.